{"product_id":"coo-bcg-matrix","title":"The Cooper Companies, Inc. (COO): BCG Matrix [June-2026 Updated]","description":"\u003cp\u003eThis ready-made analysis gives you a clear, research-based view of The Cooper Companies, Inc. across Stars, Cash Cows, Question Marks, and Dogs, so you can quickly see where growth, market share, and capital should matter most. You'll learn why CooperVision's \u003cstrong\u003e$723.5M\u003c\/strong\u003e Q2 2026 revenue, roughly one-third global contact lens share, MyDay and MiSight growth, Biofinity's steady cash generation, CooperSurgical's \u003cstrong\u003e$358.0M\u003c\/strong\u003e Q2 revenue, and the \u003cstrong\u003e$271.6M\u003c\/strong\u003e litigation charge all shape portfolio balance, risk, and capital allocation through fiscal 2026.\u003c\/p\u003e\u003ch2\u003eThe Cooper Companies, Inc. - BCG Matrix Analysis: Stars\u003c\/h2\u003e\n\u003cp\u003eThe Cooper Companies, Inc.'s Star businesses are centered on CooperVision's premium contact lens portfolio, especially MyDay and MiSight. These products combine strong growth with large market presence, which is the core BCG Star profile.\u003c\/p\u003e\n\n\u003cp\u003eStars are business units with high market growth and high relative market share. They usually need continued investment to defend position, but they also have the scale to become major cash generators later. In The Cooper Companies, Inc.'s case, CooperVision fits this pattern because it held roughly one-third of global contact lens wearers in an $11B market while still posting above-market growth.\u003c\/p\u003e\n\n\u003cp\u003eCooperVision generated $723.5M of revenue in Q2 2026, up \u003cstrong\u003e8.0%\u003c\/strong\u003e reported and \u003cstrong\u003e4.0%\u003c\/strong\u003e organically. That matters because organic growth shows the business is expanding without relying only on acquisitions or foreign exchange. For a mature medical device company, that rate is strong and supports Star classification.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eStar Candidate\u003c\/th\u003e\n\u003cth\u003eGrowth Signal\u003c\/th\u003e\n\u003cth\u003eMarket Position\u003c\/th\u003e\n\u003cth\u003eWhy It Fits Star\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyDay\u003c\/td\u003e\n\u003ctd\u003eDouble-digit revenue growth in Q2 2026\u003c\/td\u003e\n\u003ctd\u003ePremium silicone hydrogel lens franchise\u003c\/td\u003e\n \u003ctd\u003eHigh growth plus strong brand and distribution scale\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiSight\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23.0%\u003c\/strong\u003e revenue growth in Q1 2026\u003c\/td\u003e\n \u003ctd\u003eMyopia management lens for children\u003c\/td\u003e\n\u003ctd\u003eExpanding niche with long runway and strategic relevance\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooperVision premium daily disposable portfolio\u003c\/td\u003e\n \u003ctd\u003eFY 2026 revenue guidance of $2.88B to $2.91B\u003c\/td\u003e\n \u003ctd\u003eAbout one-third of global contact lens wearers\u003c\/td\u003e\n \u003ctd\u003eLarge installed base and continued premium mix shift\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eMYDAY AND MISIGHT LEAD the Star case because they sit in the fastest-growing part of the portfolio. MyDay delivered double-digit revenue growth in Q2 2026, while MiSight grew \u003cstrong\u003e23.0%\u003c\/strong\u003e in Q1 2026 after Japan launches. That tells you the company is not just defending share; it is still expanding into premium categories and new regions.\u003c\/p\u003e\n\n\u003cp\u003eMyDay matters because it sits in the premium daily disposable silicone hydrogel category, which is where consumer and practitioner demand is moving. Silicone hydrogel lenses let more oxygen reach the eye than standard hydrogel lenses, so they are often positioned as a higher-performance option. MyDay multifocal and toric launches extend that platform into adjacent prescriptions, which widens the addressable market and supports recurring revenue.\u003c\/p\u003e\n\n\u003cp\u003eMiSight is important for a different reason. It targets pediatric myopia management, a category with a clear long-term growth driver as more children need vision correction earlier in life. The company's Q1 2026 \u003cstrong\u003e23.0%\u003c\/strong\u003e growth after Japan launches shows the category can scale internationally. In BCG terms, that combination of high growth and strategic relevance supports Star treatment even if the current revenue base is smaller than the core lens franchise.\u003c\/p\u003e\n\n\u003cp\u003ePREMIUM DAILY DISPOSABLE SHIFT is the main strategic engine behind this Star classification. CooperVision's business is centered on premium daily disposable silicone hydrogel contact lenses, and that is the clearest high-growth, high-share investment zone in the portfolio. The company's premium upgrade strategy is tied to Aquaform technology, which supports comfort and oxygen permeability, two buying factors that matter in contact lenses.\u003c\/p\u003e\n\n\u003cp\u003eCooperVision remained the largest revenue contributor at \u003cstrong\u003e67.0%\u003c\/strong\u003e of company sales in June 2026. That scale matters because large share gives the company better leverage over manufacturing, distribution, and retailer relationships. It also gives management room to keep investing in product launches while still maintaining profitability.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMyDay supports premium daily disposable growth.\u003c\/li\u003e\n \u003cli\u003eMyDay multifocal and toric broaden the prescription base.\u003c\/li\u003e\n \u003cli\u003eMiSight adds a high-growth pediatric myopia category.\u003c\/li\u003e\n \u003cli\u003eAquaform technology strengthens product differentiation.\u003c\/li\u003e\n \u003cli\u003eCooperVision's \u003cstrong\u003e67.0%\u003c\/strong\u003e revenue contribution shows scale behind the strategy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMYOPIA MANAGEMENT EXPANDS the Star profile because it adds a long-duration growth theme. Myopia correction in children is becoming a bigger industry focus, and that expands the addressable market for MiSight. The company's Q1 2026 growth of \u003cstrong\u003e23.0%\u003c\/strong\u003e after Japanese launches shows that execution is matching the opportunity.\u003c\/p\u003e\n\n\u003cp\u003eThe broader contact lens market was about \u003cstrong\u003e$11B\u003c\/strong\u003e in June 2026, which gives CooperVision a large commercial base to work from. A large market matters in BCG analysis because a high-share business can keep growing without immediately hitting saturation. CooperVision's Q2 2026 revenue of \u003cstrong\u003e$723.5M\u003c\/strong\u003e also shows that it can scale while still investing in specialty segments like myopia management.\u003c\/p\u003e\n\n\u003cp\u003eGEOGRAPHIC SHARE ADVANCE reinforces the Star view because the company is still growing across major regions. In Q2 2026, Americas revenue grew \u003cstrong\u003e7.0%\u003c\/strong\u003e and EMEA revenue grew \u003cstrong\u003e6.0%\u003c\/strong\u003e. Those are healthy results for a business already operating at scale.\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific revenue fell \u003cstrong\u003e6.0%\u003c\/strong\u003e to $130.6M, so the story is not uniform across all regions. Even so, CooperVision still held roughly one-third of global contact lens wearers, which is a strong competitive position. J\u0026amp;J Vision Care held \u003cstrong\u003e35.0%\u003c\/strong\u003e to \u003cstrong\u003e40.0%\u003c\/strong\u003e market share and Alcon held \u003cstrong\u003e14.2%\u003c\/strong\u003e, so CooperVision remains one of the few global scale leaders.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRegion\u003c\/th\u003e\n\u003cth\u003eQ2 2026 Revenue Trend\u003c\/th\u003e\n\u003cth\u003eAnalysis\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmericas\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e7.0%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eShows steady demand in the largest commercial region\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMEA\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e6.0%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSignals broad-based adoption and channel resilience\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia Pacific\u003c\/td\u003e\n\u003ctd\u003eDown \u003cstrong\u003e6.0%\u003c\/strong\u003e to $130.6M\u003c\/td\u003e\n\u003ctd\u003eWeakness exists, but it does not erase the global share position\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe company's FY 2026 organic revenue guidance of \u003cstrong\u003e3.5%\u003c\/strong\u003e to \u003cstrong\u003e4.5%\u003c\/strong\u003e still looks respectable for a business of this size. That range shows management expects continued expansion even from a large installed base. In BCG terms, that is exactly what a Star should do: grow faster than the market while protecting a strong share position.\u003c\/p\u003e\n\n\u003cp\u003eGROWTH FUNDED BY SCALE is what keeps the Star quadrant sustainable. CooperVision's leadership position gives it the cash and channel reach needed to support premium product development, distribution, and sales execution. That is important because Stars usually consume capital before they turn into Cash Cows.\u003c\/p\u003e\n\n\u003cp\u003eCompany-wide free cash flow in Q2 2026 was \u003cstrong\u003e$96.4M\u003c\/strong\u003e. Free cash flow means cash left after operating costs and capital spending, and it matters because it shows whether the business can fund growth internally. Cooper ended the quarter with \u003cstrong\u003e$2.3B\u003c\/strong\u003e in net debt and \u003cstrong\u003e$20.9M\u003c\/strong\u003e of interest expense, so disciplined cash generation still matters.\u003c\/p\u003e\n\n\u003cp\u003eThe remaining share repurchase authorization of \u003cstrong\u003e$860.8M\u003c\/strong\u003e shows management still has flexibility to return capital while supporting growth investments. The business also benefits from \u003cstrong\u003e$50M\u003c\/strong\u003e of annual savings from the Q4 2025 restructuring starting in fiscal 2026. Those savings improve the funding base for premium innovation and channel expansion.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$96.4M\u003c\/strong\u003e of Q2 2026 free cash flow supports internal funding.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$2.3B\u003c\/strong\u003e of net debt means capital allocation must stay disciplined.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$20.9M\u003c\/strong\u003e of interest expense reduces financial flexibility but remains manageable in context.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$860.8M\u003c\/strong\u003e of repurchase authorization signals spare capital capacity.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$50M\u003c\/strong\u003e of annual restructuring savings improves operating leverage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor academic work, the Star classification is strongest when you connect market share, growth rate, and strategic investment. In this case, CooperVision's premium daily disposable franchise, myopia management growth, and one-third global wearer share all support the same argument: the business is growing in a large market and still has room to expand.\u003c\/p\u003e\u003ch2\u003eThe Cooper Companies, Inc. - BCG Matrix Analysis: Cash Cows\u003c\/h2\u003e\n\u003cp\u003eThe Cooper Companies, Inc. has a strong Cash Cow profile in its mature vision care and surgical franchises. These businesses combine large market share, steady growth, high margins, and consistent free cash flow, which lets them fund investment, debt service, and capital returns.\u003c\/p\u003e\n\n\u003cp\u003eBiofinity is the clearest Cash Cow inside CooperVision because it sits at the center of a mature lens base with scale, recurring demand, and strong operating leverage. In Q2 2026, CooperVision generated \u003cstrong\u003e$723.5M\u003c\/strong\u003e of revenue and represented \u003cstrong\u003e67.0%\u003c\/strong\u003e of total company sales, showing how much of the company still depends on a core cash-generating portfolio.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Cow Area\u003c\/td\u003e\n\u003ctd\u003eQ2 2026 Revenue\u003c\/td\u003e\n\u003ctd\u003eGrowth Profile\u003c\/td\u003e\n\u003ctd\u003eWhy It Fits Cash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiofinity anchor platform\u003c\/td\u003e\n\u003ctd\u003e$723.5M segment revenue for CooperVision\u003c\/td\u003e\n \u003ctd\u003e5.0% organic growth\u003c\/td\u003e\n\u003ctd\u003eLarge installed base, repeat purchases, and scale support steady cash generation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMature lens base\u003c\/td\u003e\n\u003ctd\u003eIncluded in CooperVision mix\u003c\/td\u003e\n\u003ctd\u003eAmericas 7.0%, EMEA 6.0%\u003c\/td\u003e\n\u003ctd\u003eModerate growth and leadership in a large market allow cash harvesting\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOffice and Surgical Products\u003c\/td\u003e\n\u003ctd\u003e$214.0M\u003c\/td\u003e\n\u003ctd\u003e4.0% organic growth\u003c\/td\u003e\n\u003ctd\u003eStable women's health and procedural demand supports predictable cash flow\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany-wide core operations\u003c\/td\u003e\n\u003ctd\u003e$1.082B\u003c\/td\u003e\n\u003ctd\u003eRevenue base supported by mature franchises\u003c\/td\u003e\n \u003ctd\u003eStrong margins and free cash flow show efficient cash conversion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe mature lens base is the main reason this business qualifies as a Cash Cow. CooperVision holds roughly one-third of global contact lens wearers, which gives it the market share needed to produce cash without relying on aggressive reinvestment. In BCG terms, that is the ideal Cash Cow setup: high relative market share in a slow-to-moderate growth market.\u003c\/p\u003e\n\n\u003cp\u003eThe company's Q2 2026 non-GAAP operating margin reached \u003cstrong\u003e27.5%\u003c\/strong\u003e, up \u003cstrong\u003e260 basis points\u003c\/strong\u003e year over year. A margin increase like this matters because it shows that each dollar of sales is producing more operating profit, which strengthens the cash available after expenses. Free cash flow of \u003cstrong\u003e$96.4M\u003c\/strong\u003e in the quarter, despite \u003cstrong\u003e$86.4M\u003c\/strong\u003e of capital expenditures, confirms that the business is generating cash after funding maintenance and growth investment.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAmericas growth of \u003cstrong\u003e7.0%\u003c\/strong\u003e and EMEA growth of \u003cstrong\u003e6.0%\u003c\/strong\u003e show a mature but still reliable demand base.\u003c\/li\u003e\n \u003cli\u003eThe contact lens market is about \u003cstrong\u003e$11B\u003c\/strong\u003e, giving the company scale in a large established category.\u003c\/li\u003e\n \u003cli\u003eHigh market share reduces the need for heavy discounting and supports stable pricing power.\u003c\/li\u003e\n \u003cli\u003eStable cash generation matters because it can fund R\u0026amp;D, acquisitions, debt reduction, and share repurchases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOffice and Surgical Products also fits the Cash Cow logic, even though it is smaller than vision care. The business generated \u003cstrong\u003e$214.0M\u003c\/strong\u003e of Q2 2026 revenue and grew \u003cstrong\u003e4.0%\u003c\/strong\u003e organically, which is steady rather than fast. That kind of growth is useful in a mature portfolio because it adds dependable cash without requiring the kind of heavy spending usually needed in high-growth markets.\u003c\/p\u003e\n\n\u003cp\u003eThe broader CooperSurgical segment posted \u003cstrong\u003e$358.0M\u003c\/strong\u003e of revenue in Q2 2026, but the Office and Surgical Products piece is the more stable cash engine inside it. Women's health and procedural products tend to have recurring demand and lower volatility than early-stage categories, so they fit the Cash Cow profile better than a question mark or star in the BCG Matrix.\u003c\/p\u003e\n\n\u003cp\u003eCost discipline strengthens the cash story. The Q4 2025 restructuring was completed to deliver \u003cstrong\u003e$50M\u003c\/strong\u003e in annual savings starting in fiscal 2026. Lower fixed costs improve conversion from revenue to earnings and cash, which is why the company could report \u003cstrong\u003e$1.21\u003c\/strong\u003e in non-GAAP earnings per share in Q2 2026 while still maintaining a strong margin base.\u003c\/p\u003e\n\n\u003cp\u003eThe company also returned cash to shareholders. It repurchased \u003cstrong\u003e$13.1M\u003c\/strong\u003e of stock in Q2 2026 at an average price of \u003cstrong\u003e$75.84\u003c\/strong\u003e, and remaining repurchase authority of \u003cstrong\u003e$860.8M\u003c\/strong\u003e shows it still has room to buy back shares if cash generation stays strong. Buybacks are a common use of Cash Cow cash because mature businesses often produce more cash than they need for internal reinvestment.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow and Capital Allocation Metric\u003c\/td\u003e\n\u003ctd\u003eQ2 2026 Value\u003c\/td\u003e\n\u003ctd\u003eInterpretation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.082B\u003c\/td\u003e\n\u003ctd\u003eLarge base of recurring sales supports cash generation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP operating margin\u003c\/td\u003e\n\u003ctd\u003e27.5%\u003c\/td\u003e\n\u003ctd\u003eShows strong profitability from core operations\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow\u003c\/td\u003e\n\u003ctd\u003e$96.4M\u003c\/td\u003e\n\u003ctd\u003eCash left after operating needs and capex\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital expenditures\u003c\/td\u003e\n\u003ctd\u003e$86.4M\u003c\/td\u003e\n\u003ctd\u003eInvestment level remains manageable for a mature business\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock repurchases\u003c\/td\u003e\n\u003ctd\u003e$13.1M\u003c\/td\u003e\n\u003ctd\u003eEvidence of surplus cash after funding operations\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemaining repurchase authorization\u003c\/td\u003e\n\u003ctd\u003e$860.8M\u003c\/td\u003e\n\u003ctd\u003eShows financial flexibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe business mix also supports the Cash Cow label. Vision care represented \u003cstrong\u003e67.0%\u003c\/strong\u003e of sales, while surgical and fertility contributed the remaining \u003cstrong\u003e33.0%\u003c\/strong\u003e. That split matters because the larger, more mature vision care base is the main source of dependable cash, while the smaller surgical platform adds diversification and additional cash flow.\u003c\/p\u003e\n\n\u003cp\u003eTax and leverage are manageable for a mature cash business. The effective tax rate was \u003cstrong\u003e15.4%\u003c\/strong\u003e in Q2 2026, close to the \u003cstrong\u003e15.5%\u003c\/strong\u003e fiscal 2026 guidance, which supports predictability in net income and cash planning. Net debt of \u003cstrong\u003e$2.3B\u003c\/strong\u003e is meaningful, but it is manageable relative to the company's scale and recurring cash generation, especially when free cash flow stays positive.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable revenue reduces earnings volatility.\u003c\/li\u003e\n \u003cli\u003eHigh margins improve cash conversion from sales.\u003c\/li\u003e\n \u003cli\u003eModerate capex protects free cash flow.\u003c\/li\u003e\n\u003cli\u003eShare buybacks show excess cash after operations.\u003c\/li\u003e\n \u003cli\u003eGuided tax rates improve forecasting reliability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor academic work, this makes a clear Cash Cow case study. The company's mature market position, strong operating margin, steady free cash flow, and shareholder returns show how a leadership franchise in a low-to-moderate growth market can keep generating cash long after the fastest growth phase has passed.\u003c\/p\u003e\n\u003ch2\u003eThe Cooper Companies, Inc. - BCG Matrix Analysis: Question Marks\u003c\/h2\u003e\n\n\u003cp\u003eThe Cooper Companies, Inc. has several businesses that fit the Question Mark quadrant because they operate in attractive growth areas but do not show clear, dominant share positions in the data provided. That means these units need more capital, sharper execution, and closer portfolio review before they can be treated as Stars.\u003c\/p\u003e\n\n\u003cp\u003eQuestion Marks are the parts of the portfolio where growth is real, but leadership is not yet secure. For The Cooper Companies, Inc., that matters because capital can either build scale in the right businesses or get tied up in units that never earn enough share to justify the spend.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eBusiness Area\u003c\/td\u003e\n\u003ctd\u003eRecent Data Point\u003c\/td\u003e\n\u003ctd\u003eBCG Signal\u003c\/td\u003e\n\u003ctd\u003eWhy It Fits Question Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooperSurgical Fertility\u003c\/td\u003e\n\u003ctd\u003e$144.0M Q2 2026 revenue, 10.0% organic growth\u003c\/td\u003e\n \u003ctd\u003eHigh growth, unclear share\u003c\/td\u003e\n\u003ctd\u003eGrowth is strong, but the market-share position is not shown as dominant\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooperSurgical Platform\u003c\/td\u003e\n\u003ctd\u003e$358.0M Q2 revenue, 33.0% of company sales\u003c\/td\u003e\n \u003ctd\u003eStrategic uncertainty\u003c\/td\u003e\n\u003ctd\u003eImportant to the group, but future ownership and structure are unresolved\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiSight and Myopia Management\u003c\/td\u003e\n\u003ctd\u003e23.0% Q1 2026 growth after Japan launches\u003c\/td\u003e\n \u003ctd\u003eFast-growing category\u003c\/td\u003e\n\u003ctd\u003eDemand is rising, but category leadership is not clearly disclosed\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew CSI Acquisitions\u003c\/td\u003e\n\u003ctd\u003e$33.5M fertility acquisition, $50M Cook Medical installment due November 1, 2025\u003c\/td\u003e\n \u003ctd\u003ePortfolio buildout\u003c\/td\u003e\n\u003ctd\u003eThe company is still buying capability, not just harvesting mature cash flows\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCooperSurgical Fertility\u003c\/strong\u003e is a classic Question Mark. Fertility revenue reached \u003cstrong\u003e$144.0M\u003c\/strong\u003e in Q2 2026 and grew \u003cstrong\u003e10.0%\u003c\/strong\u003e organically, which shows healthy demand. But the available data do not show that The Cooper Companies, Inc. has a clear market-share lead, so the business looks promising without being proven. The June 2024 acquisition of a fertility business focused on sperm separation devices for \u003cstrong\u003e$33.5M\u003c\/strong\u003e shows management is still investing to widen the product set. Higher R\u0026amp;D expense, including project spend and pharmacovigilance fees, also tells you the company is still funding development rather than harvesting mature returns.\u003c\/p\u003e\n\n\u003cp\u003eThat matters strategically because Question Marks absorb capital fast. If the fertility platform gains scale, it can move toward Star status. If not, it risks becoming a weak return on invested capital, which is the amount of profit generated for each dollar of capital used.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCooperSurgical as a whole\u003c\/strong\u003e also carries Question Mark traits because of strategic uncertainty. The Board announced a formal strategic review in December 2025 to simplify operations and improve long-term shareholder value. By June 2026, management said it had received significant indications of interest for the CooperSurgical business. At the same time, CSI still generated \u003cstrong\u003e$358.0M\u003c\/strong\u003e in Q2 revenue and made up \u003cstrong\u003e33.0%\u003c\/strong\u003e of company sales. That means the segment is economically important, but its future ownership structure is not settled.\u003c\/p\u003e\n\n\u003cp\u003eFY 2026 CSI revenue guidance of \u003cstrong\u003e$1.40B to $1.41B\u003c\/strong\u003e confirms the segment is too large to ignore. In BCG terms, that is exactly where a Question Mark creates tension: high relevance, uncertain end state, and a need to decide whether to invest, restructure, or sell.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh revenue base supports continued strategic attention.\u003c\/li\u003e\n \u003cli\u003eUnclear end state limits long-term planning visibility.\u003c\/li\u003e\n \u003cli\u003ePotential buyer interest creates optionality for capital allocation.\u003c\/li\u003e\n \u003cli\u003eWithout clear ownership clarity, execution risk stays elevated.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMiSight and the myopia expansion bet\u003c\/strong\u003e also fit Question Mark territory. MiSight posted \u003cstrong\u003e23.0%\u003c\/strong\u003e growth in Q1 2026 after Japan launches, which signals strong demand in pediatric myopia management. The broader contact lens market is about \u003cstrong\u003e$11B\u003c\/strong\u003e, and myopia treatment demand is rising globally, so the addressable market is attractive. CooperVision is also expanding MyDay multifocal and toric lenses, which broadens the platform.\u003c\/p\u003e\n\n\u003cp\u003eStill, growth alone does not make this a Star. The company did not disclose a clear category-leading share in pediatric myopia management, and Asia Pacific softness in Japan and China shows the market is uneven. For academic analysis, that is important because Question Marks are usually defined by the gap between market opportunity and actual share capture.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNew acquisitions\u003c\/strong\u003e strengthen the Question Mark case. The \u003cstrong\u003e$50M\u003c\/strong\u003e final installment for Cook Medical assets due November 1, 2025, plus the \u003cstrong\u003e$33.5M\u003c\/strong\u003e fertility acquisition, show that CooperSurgical is still assembling capabilities. Q2 2026 CooperSurgical fertility revenue of \u003cstrong\u003e$144.0M\u003c\/strong\u003e and office and surgical revenue of \u003cstrong\u003e$214.0M\u003c\/strong\u003e point to a mixed portfolio rather than a fully settled market leader across each category.\u003c\/p\u003e\n\n\u003cp\u003eThe segment also faced a \u003cstrong\u003e$271.6M\u003c\/strong\u003e litigation charge in Q2 2026. That weakens near-term earnings quality, which is the degree to which profits are repeatable and backed by core operations. So even where growth is solid, legal costs and integration spending can reduce the cash available for expansion.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCapital allocation optionality\u003c\/strong\u003e is one of the clearest Question Mark signals in this business. The company had \u003cstrong\u003e$860.8M\u003c\/strong\u003e of remaining repurchase authorization and a June 2026 market capitalization of \u003cstrong\u003e$12.14B\u003c\/strong\u003e at a \u003cstrong\u003e$62.02\u003c\/strong\u003e share price. At the same time, CooperSurgical is under strategic review and has attracted indications of interest. FY 2026 company revenue guidance of \u003cstrong\u003e$4.285B to $4.321B\u003c\/strong\u003e and non-GAAP EPS guidance of \u003cstrong\u003e$4.58 to $4.66\u003c\/strong\u003e show the overall group is still expanding.\u003c\/p\u003e\n\n\u003cp\u003eThat creates a capital choice problem. Management can keep funding the platform, separate it, or sell it. In BCG terms, that flexibility is what makes a Question Mark: the business may become a Star if execution is strong, but it also may need to be exited if returns do not justify the investment.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuybacks signal that management still has capital return capacity.\u003c\/li\u003e\n \u003cli\u003eStrategic review suggests the portfolio may be reshaped.\u003c\/li\u003e\n \u003cli\u003eRevenue growth supports reinvestment, but not automatic expansion.\u003c\/li\u003e\n \u003cli\u003eLegal and integration costs raise the hurdle for future capital deployment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe right academic takeaway is that these units should not be judged only on revenue growth. They must be measured against market share, capital intensity, execution risk, and strategic fit. In The Cooper Companies, Inc., the Question Mark businesses are attractive enough to fund, but not yet strong enough to treat as settled winners.\u003c\/p\u003e\u003ch2\u003eThe Cooper Companies, Inc. - BCG Matrix Analysis: Dogs\u003c\/h2\u003e\n\u003cp\u003eThe weakest parts of The Cooper Companies, Inc. fit the Dogs category because they show low growth, weak momentum, and heavy operational or legal drag. The clearest examples are the legacy hydrogel contact lens base in Asia Pacific and the embryo culture media franchise inside CooperSurgical.\u003c\/p\u003e\n\n\u003cp\u003eIn BCG Matrix terms, a Dog is a business with low relative market share in a low-growth market. That matters because these units usually tie up capital, management attention, and cash without producing strong returns. For The Cooper Companies, Inc., the issue is not the entire company, but specific product lines and legacy exposures that are being de-emphasized or burdened by disputes and cost pressure.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eBusiness area\u003c\/td\u003e\n\u003ctd\u003eRecent signal\u003c\/td\u003e\n\u003ctd\u003eBCG reading\u003c\/td\u003e\n\u003ctd\u003eWhy it matters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC legacy hydrogel contact lenses\u003c\/td\u003e\n\u003ctd\u003eRevenue fell \u003cstrong\u003e6.0%\u003c\/strong\u003e to \u003cstrong\u003e$130.6M\u003c\/strong\u003e in Q2 2026\u003c\/td\u003e\n \u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eDeclining revenue and active portfolio rationalization show weak strategic priority\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan and China vision demand\u003c\/td\u003e\n\u003ctd\u003eManagement cited softness in both markets\u003c\/td\u003e\n \u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eLow momentum in key markets reduces the chance of near-term recovery\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmbryo culture media\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$271.6M\u003c\/strong\u003e net pre-tax charge after litigation liability and insurance recovery\u003c\/td\u003e\n \u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eLegal overhang and cash drag weaken economics\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariffs and freight pressure\u003c\/td\u003e\n\u003ctd\u003eFull-year 2026 tariff expense estimated at \u003cstrong\u003e$22M\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eDog-like pressure\u003c\/td\u003e\n\u003ctd\u003eHigher costs compress margins in lower-growth lines with weaker pricing power\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAPAC legacy hydrogel\u003c\/strong\u003e is the clearest Dog. The company said Asia Pacific contact lens revenue fell \u003cstrong\u003e6.0%\u003c\/strong\u003e to \u003cstrong\u003e$130.6M\u003c\/strong\u003e in Q2 2026, and management explicitly said it is continuing portfolio rationalization for legacy hydrogel contact lenses in the region. That is the opposite of a growth story. When a company is actively shrinking or simplifying a product set, it usually means the line no longer deserves much reinvestment. In BCG terms, that is classic Dog behavior: low growth, weak competitive position, and limited strategic relevance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJapan and China softness\u003c\/strong\u003e deepen the same conclusion. Management said market weakness in those countries is hurting the vision business, even though CooperVision still grew \u003cstrong\u003e8.0%\u003c\/strong\u003e reported overall. That gap matters. It shows the growth engine is coming from premium franchises, while the older APAC hydrogel base is losing relevance. If growth is concentrated in one side of the portfolio and the older base is being rationalized, the lagging segment belongs in Dogs because it is not the source of future expansion.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eRevenue decline signals weak demand, not temporary noise.\u003c\/li\u003e\n \u003cli\u003ePortfolio rationalization signals management is trimming the line, not expanding it.\u003c\/li\u003e\n \u003cli\u003eSoftness in Japan and China shows the problem is regional, not isolated.\u003c\/li\u003e\n \u003cli\u003ePremium products are offsetting the weakness, which makes the legacy base less important.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecall-impacted media\u003c\/strong\u003e inside CooperSurgical also fits Dogs. The company said the embryo culture media franchise remained weighed down by the December 2023 voluntary recall. In Q2 2026, it recorded a \u003cstrong\u003e$324.1M\u003c\/strong\u003e litigation liability, partially offset by \u003cstrong\u003e$52.5M\u003c\/strong\u003e of insurance recovery, for a net pre-tax charge of \u003cstrong\u003e$271.6M\u003c\/strong\u003e. Management also said more than \u003cstrong\u003e95.0%\u003c\/strong\u003e of claims related to the recall had been settled by June 2026. Even with settlements advancing, the franchise still carries a legal shadow, no clear growth profile in the disclosed data, and a real cash and management burden. That is not a healthy market leader. It looks like a Dog because it consumes resources while offering limited strategic upside.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLegal drain on CooperSurgical\u003c\/strong\u003e is another Dog-like issue. The Q2 2026 GAAP net loss was \u003cstrong\u003e$(78.1M)\u003c\/strong\u003e, driven by the \u003cstrong\u003e$271.6M\u003c\/strong\u003e litigation charge. The company also faces a tort product liability case filed in New Mexico in June 2025. Its FY 2026 free cash flow guidance of about \u003cstrong\u003e$650M\u003c\/strong\u003e excludes litigation payouts, which means legal costs can still reduce cash available for debt reduction, acquisitions, or reinvestment. A business that produces cash but then loses flexibility to legal claims is not acting like a growth asset. It behaves like a Dog because the economics are being dragged down by non-operating risk.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTariff and freight pressure\u003c\/strong\u003e adds another layer. The company said higher costs from tariffs and freight remained material drivers of gross margin pressure in June 2026. It estimated full-year 2026 tariff expense at \u003cstrong\u003e$22M\u003c\/strong\u003e, even after possible refunds of up to \u003cstrong\u003e$15M\u003c\/strong\u003e. Adverse foreign exchange was mostly offset by operational efficiencies, but that still means the company had to work just to hold the line. In a low-growth or declining product category, weak pricing power makes cost inflation more damaging. That is why this pressure reinforces Dog status: the business is spending effort to defend margins instead of expanding returns.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eLegal charges reduce reported earnings and can distort operating performance.\u003c\/li\u003e\n \u003cli\u003eCash settlement risk matters because free cash flow is what funds growth and returns.\u003c\/li\u003e\n \u003cli\u003eTariffs and freight costs hit margins harder when demand is weak.\u003c\/li\u003e\n \u003cli\u003eOffsetting costs through efficiencies is defensive, not a sign of strength.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndicator\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eInterpretation for BCG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC contact lens revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$130.6M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLegacy base is shrinking\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC revenue change\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-6.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNegative momentum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall CooperVision growth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8.0%\u003c\/strong\u003e reported\u003c\/td\u003e\n\u003ctd\u003eGrowth is coming from other franchises, not legacy hydrogel\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLitigation liability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$324.1M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHeavy legal overhang\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsurance recovery\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.5M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOnly partial offset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet pre-tax charge\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$271.6M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDirect hit to profitability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClaims settled by June 2026\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 95.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIssue is advanced, but still costly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2026 tariff expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMargin pressure remains meaningful\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePossible tariff refunds\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$15M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePartial relief, not full removal of pressure\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFor academic work, you can treat these Dog segments as examples of businesses that should be harvested, managed for cash, or gradually exited rather than expanded. The key strategic point is that the company's premium eye care franchises and core surgical platforms are carrying the growth profile, while these older or burdened units mainly create drag.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601020121237,"sku":"coo-bcg-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/coo-bcg-matrix.png?v=1740222107","url":"https:\/\/dcf-model.com\/pt\/products\/coo-bcg-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}